linjc16/ctgov huggingface dataset:
Identifying the Gaps in the Diagnosis and Management of Hepatitis C

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to identify the gaps in diagnosing and managing hepatitis C infected patients so that interventions can be targeted to address these problem areas in order to optimize care of these patients.

Official Title
-----------------
Identifying the Gaps in the Diagnosis and Management of Hepatitis C

Conditions
-----------------
Hepatitis C

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Every patient diagnosed with hepatitis C Exclusion Criteria: Patients younger than 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| This is a retrospective observational study. The outcome measure would be the number of patients who are actually followed and treated for hepatitis C after they have been diagnosed |  | One year |
Prediction of Pelvic Adhesions at Repeat Cesarean Delivery

Study Overview
=================
Brief Summary
-----------------
Several methods have been used to predict adhesions after abdominal operations. High-resolution ultrasonography, magnetic resonance imaging and scar healing properties were the methods that were evaluated in the English literature for this study. Estimating the likelihood of adhesions and related complications after prior surgery and assessing the severity of adhesion formation after surgery is not easy. Anticipating adhesions is very important to preventing complications by ensuring that the necessary preoperative preparations are in place and/or that appropriate cases are referred to a tertiary center.

Official Title
-----------------
Predictive Value of Striae Gravidarum Severity and Cesarean Scar Characteristics for Pelvic Adhesions at Repeat Cesarean Delivery

Conditions
-----------------
Decrease Maternal Morbidity

Intervention / Treatment
-----------------
* Other: Davey score for striae gravidarum


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women with at least previous one cesarean Full term (37- 41 weeks) Women accepted to participate in the study Exclusion Criteria: History of pelvic inflammatory disease History of endometriosis Previous pelvic surgery other than cesarean History of wound site infections History of long corticosteroid use Women with midline incisions Women with placenta accreta Women refuse to participate in the study
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Davey score for striae gravidarum|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of of abdominal adhesions in relation to striae scoring system |  | 30 min |
Comparison of Conventional GlideScope to Single-Use GlideScope Cobalt for Orotracheal Intubation

Study Overview
=================
Brief Summary
-----------------
Patients presenting for elective surgery requiring orotracheal intubation will be randomized to being intubated with either the conventional (reusable) GlideScope videolaryngoscope or the single-use GlideScope videolaryngoscope. The primary outcome is time to intubation.

Official Title
-----------------
Comparison of Conventional GlideScope to Single-Use GlideScope Cobalt for Orotracheal Intubation

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Device: Conventional (reusable) Glidescope
* Device: Single-use Glidescope videolaryngoscope


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient who is ≥ 18 yrs. coming for elective surgery. Endotracheal tube is indicated for the procedure in the opinion of the attending anesthesiologist. Any operator who has performed ≥ 10 GlideScope intubations. Exclusion Criteria: Any patient in whom the use of the GlideScope is contraindicated in the opinion of the attending anesthesiologist. Any patient with cervical spine abnormalities. Any patients with known or probable difficult airways (this rare occurrence is unlikely to be evenly distributed between the groups and could skew the data). Any patient requiring rapid sequence induction.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Conventional Glidescope<br> | Device: Conventional (reusable) Glidescope<br> <br> |
| Experimental: Single-use Glidescope<br> | Device: Single-use Glidescope videolaryngoscope<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to intubation (seconds) |  | Immediate | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ease of intubation |  | after intubation | 
| Number of intubation attempts per group |  | after intubation | 
| Incidence of trauma in each group |  | after intubation | 
| Number of failures to intubate per group |  | after intubation | 
| Use of external laryngeal pressure per group |  | after intubation | 
| Laryngoscopic grade distribution in each group |  | after intubation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
GlideScope, cobalt, single-use, intubation, airway, Elective surgical patients requiring orotracheal intubation
Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Estrogen can stimulate the growth of endometrial cancer cells. Hormone therapy using raloxifene may fight endometrial cancer by reducing the production of estrogen. PURPOSE: Phase II trial to study the effectiveness of raloxifene in treating patients who have persistent or recurrent endometrial cancer.

Detailed Description
-----------------
OBJECTIVES: I. Determine response rate and time to disease progression in patients with recurrent endometrial cancer treated with raloxifene. II. Determine overall survival in these patients treated with this regimen. III. Determine the toxicity of raloxifene in this patient population. OUTLINE: Patients receive oral raloxifene daily. Treatment continues indefinitely in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months. PROJECTED ACCRUAL: A total of 13-50 patients will be accrued for this study within 2.5 years.

Official Title
-----------------
Phase II Study of Raloxifene in Recurrent Endometrial Cancer

Conditions
-----------------
Endometrial Cancer

Intervention / Treatment
-----------------
* Drug: raloxifene


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Recurrent endometrial cancer Evidence of persistent or recurrent disease 4 weeks following primary treatment with radiation and surgery Bidimensionally measurable disease Not a candidate for curative salvage radiotherapy PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-3 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Cardiovascular: No history of unexplained or uncontrolled thromboembolic disease No active thromboembolic disease Other: No active or uncontrolled second malignancy HIV negative PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks since prior chemotherapy for early stage or advanced endometrial cancer Endocrine therapy: At least 4 weeks since prior hormonal therapy for early stage or advanced endometrial cancer Radiotherapy: See Disease Characteristics Surgery: See Disease Characteristics

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: raloxifene|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
recurrent endometrial carcinoma
Blood microRNA Depression Change After DHCA

Study Overview
=================
Brief Summary
-----------------
Collect the blood sample per-operation experience deep hypothermia cardiac arrest for aorta artery replacement surgery Collect the blood from the CPB machine and from intravenous injection tube which already set at different time point.

Detailed Description
-----------------
Collect the blood sample per-operation experience deep hypothermia cardiac arrest for aorta artery replacement surgery Collect the blood from the CPB machine and from intravenous injection tube which already set at different time point Test the blood sample of DHCA, analysis the correlation between miR-194 and temperature.

Official Title
-----------------
Blood microRNA Depression Change After DHCA

Conditions
-----------------
Aortic Aneurysm

Intervention / Treatment
-----------------
* Other: collect blood


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aortic dissection patients Exclusion Criteria: other organ disorder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: collect blood|collect blood at different time point|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| microRNA express change | target microRNA expression change | 1 day |
Effect of a Smartphone Application on Oral Contraceptive Adherence in College Females

Study Overview
=================
Brief Summary
-----------------
This research study is to see if smartphone applications help college women remember to take birth control better than pharmacist consultation alone. Patients will participate in this study for 6 (six) months. The study will have two groups. Patients will be randomly assigned to one group or the other. The control group will be counseled by the pharmacist on the importance of taking birth control as prescribed. The study group will get the same counseling, but will also be set up to receive reminders to take medication on a smartphone application called Dosecast.

Official Title
-----------------
Effect of a Smartphone Application on Oral Contraceptive Adherence in College Females: a Randomized-controlled Trial.

Conditions
-----------------
Adherence to Oral Contraceptive Therapy

Intervention / Treatment
-----------------
* Device: Smartphone App Dosecast


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: female gender 18-29 years of age current prescription for an OCP currently enrolled as a student at the institution associated with the pharmacy possession of a compatible smartphone. Exclusion Criteria: Pregnant patients Patients who become pregnant during the study will discontinue, but their data up until time of discontinuation will be used Patients using other forms of contraception (patch, injection, IUD, intra-vaginal ring, implant).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 29 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Smartphone App<br>The pharmacist will download and configure the Dosecast smartphone application to remind the patient to take their medication in addition to pharmacist counseling on the importance of adherence. | Device: Smartphone App Dosecast<br>* The Dosecast app is configured to remind the patient to take their medication.<br>|
| No Intervention: Counseling Alone<br>This arm will receive only counseling from the pharmacist with no other intervention. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Doses Missed | Number of doses of oral contraceptive missed over a six-month period. | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Smartphone, adherence, contraceptives, college, females
Infectious Outcomes Following Pancreas Transplantation

Study Overview
=================
Brief Summary
-----------------
The proposed protocol aims to characterize the infectious episodes in pancreas transplant recipients under the current medical care. Knowing these patients infectious risks, the types of infections that commonly affect them and the morbidity and mortality associated with it will provide valuable information in the evaluation of the safety and efficacy of the current practices. The information generated by this study will also serve as the basis for development of strategies targeting prophylaxis of infectious episodes.

Detailed Description
-----------------
The objectives of the study are: To determine what is the frequency of infectious complications following pancreas transplantation Characterize the clinical and microbiological aspects of the infectious complications following pancreas transplantation Identify predictors for infection following pancreas transplantation Determine the frequency of graft loss and associated mortality of infectious complications following pancreas transplantation

Official Title
-----------------
Infectious Outcomes Following Pancreas Transplantation

Conditions
-----------------
Pancreatic Transplantation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who underwent pancreas with or without kidney transplantation at the University of Pittsburgh Medical Center from January 1st 2002 to December 31st 2005 Patients must be above 18 years of age Patients undergoing retransplantation may be included. Exclusion Criteria: History of pancreas transplantation at another institution

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 30 day outcomes after transplantation | outcomes of transplant patients post transplant | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
transplant, pancreas
Factors Influencing Risk of Progression of Chronic Kidney Disease

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to identify typical patterns of renal function evolution in patients with stage 4 chronic kidney disease, regularly followed in nephrology consultation and included in a French cohort.

Official Title
-----------------
Factors Influencing Risk of Progression of Chronic Kidney Disease in Patients With Severe Renal Failure

Conditions
-----------------
Chronic Kidney Disease stage4

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients meeting the inclusion criteria of the ND-CRIS cohort (long-term follow-up in one of the centers participating in the research, with a GFR <60mL/min /1.73m2) Patients included in the ND-CRIS cohort on the date when the estimate of their GFR is strictly less than 30mL/min/1.73m2 and greater than or equal to 15mL/min/1.73m2 (MDRD equation). Patients should have at least two measurements of GFR <30mL/min/1.73m2 to be included, at least one of them greater than or equal to 15mL/min/1.73m2. The date of the first GFR <30mL/min/ 1.73m2 will be considered as the date of origin. Exclusion Criteria: Patients with GFR ≥30mL / min / 1.73m2 or <15mL / min / 1.73m2 Patients who do not meet the inclusion criteria of ND-CRIS cohort (dialysis patients, transplant patients, unfollowed patients)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evolution of estimated Glomerular Filtration Rate (GFR) according to MDRD equation (modification of diet in renal disease) at each visit |  | up to 3 years | 
| Time between inclusion and occurrence of the progression event | progression: initiation of an extra-renal purification technique or reduction of GFR of at least 5 mL / min / 1.73m2 compared to inclusion in FAIR-PROGRESS | up to 3 years |
Evaluation of Thyroid Exposure to Radiation Doses During Paediatric Cardiac Catheterisations Performed for Diagnosis or the Treatment of Congenital Heart Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the average risk for thyroid irradiation for any type of paediatric cardiac catheterization, based on the cummulative at-risk dose of 100 mSv, adjusted to the measured thyroid volume and to the patient's age.

Official Title
-----------------
Evaluation of Thyroid Exposure to Radiation Doses During Paediatric Cardiac Catheterisations Performed for Diagnosis or the Treatment of Congenital Heart Disease

Conditions
-----------------
Cardiac Catheterizations

Intervention / Treatment
-----------------
* Other: blood and urine samples ; Echography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Inclusion of any patient (< 18 year-old) with congenital heart disease undergoing one or more cardiac catheterization Exclusion Criteria: Exclusion of patients with any type of thyroid dissease

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: blood and urine samples ; Echography|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| exposure to radiation measure | To determine the average risk for thyroid irradiation for any type of paediatric cardiac catheterization, based on the cummulative at-risk dose of 100 mSv, adjusted to the measured thyroid volume and to the patient's age. | 2 YEARS | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| exposure to radiation measure | Fit the dose of average irradiation of the thyroid during the catheterizations to the thyroïdien volume | 2 YEARS |
The Acute Effect of Atorvastain on Renal Function in Patients With Type II Diabetes

Study Overview
=================
Brief Summary
-----------------
We wanted to test the hypothesis that acute treatment with atorvastatin changes renal sodium excretion, glomerular filtration rate, tubular function and vasoactive hormones in patients with type II diabetes, not in treatment with insulin.

Official Title
-----------------
The Acute Effect of Atorvastatin on Renal Sodium Excretion, Glomerular Filtration Rate, Tubular Function and Vasoactive Hormones in Patients With Non-Insulin Dependent Type II Diabetes.

Conditions
-----------------
Healthy Subjects

Intervention / Treatment
-----------------
* Drug: Atorvastatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: 40-70 yrs estimated GFR between 30 and 90 ml/min BMI<35 Fertile women had to use oral contraceptives or IUD HbA1c< 10% Urine-albumin<1,5 g/l Exclusion Criteria: Treatment with insulin Cerobrovascular insult or other disease of the brain Insufficiency of the heart or lungs Liverdisease with ALAT > 200 U/L hemoglobin < 7,0 mmol/l Cancer Alcohol abuse Medical treatment with psycopharmaca or/and analgetics Pregnancy and breast feeding, 10 blood donation one month before the study.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Atorvastatin|80 mg atorvastatin daily on two following days|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| GFR, clearance of sodium and lithium, fractional excretion of sodium and lithium, U-AQP-2, total sodium excretion, albumin excretion rate and free water clearance. |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AVP, Ang-II, Aldo, ANP, BNP, PRC, BP, HR. |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Atorvastatin, Renal function, Hemodynamics, Diabetes type II, sodium excretion